• Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
    • Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
    • Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 11% (cc)
    • Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
    • Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure
  • Net sales grew 2% (cc[1], +2% USD), with growth in all divisions:
    • Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications
    • Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion
    • Excluding Gleevec/Glivec, Oncology grew 11% (cc)
    • Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care
    • Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure